🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHas anyone dealt with do the heart benefits go away if i stop taking it?? Page 3

Has anyone dealt with do the heart benefits go away if i stop taking it??

CanadaChris Sat, Jul 12, 2025 at 4:16 AM 28 replies 1,496 viewsPage 3 of 6
TirzTom
Senior Member
2,789
9,876
Feb 2024
Florida
Online
Jul 19, 2025 at 12:21 AM#11
claudia_zurich said:
Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling,…

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 10 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 49" → 35" ✅ Resolved
  2. Triglycerides: 257 → 102 ✅ Resolved
  3. HDL: 33 → 59 ✅ Resolved
  4. Blood pressure: 147/95 → 120/74 ✅ Resolved
  5. Fasting glucose: 122 → 85 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

Last edited: Jul 19, 2025 at 4:21 AM
30 5josh_phd_bmore, roxy_nash, tony_orlando and 27 others
Reply Quote Save Share Report
ingrid_STO
Member
345
1,456
Jul 2024
Stockholm, SE
Jul 20, 2025 at 3:57 PM#12
Dr.KarenChen said:
Dr.MetabolicMD said: ...we don't know the long-term effects of cardiovascular risk...

This is exactly what I could not find anywhere else.

Last edited: Jul 20, 2025 at 6:57 PM
29 4COA_Karl, MikeFit_NJ, InsuranceTom and 26 others
Reply Quote Save Share Report
cory_ATX
Member
456
2,123
Jul 2024
Austin, TX
Jul 22, 2025 at 7:32 AM#13
claudia_zurich said:
Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling,…

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

InterventionNNTTimeframe
Semaglutide (MACE)673.3 years
Statins primary prevention (MI)~1005 years
Aspirin secondary prevention~772 years

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

28 3mona_PHX, andrew_nyc, Dr.EndoEP and 25 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
BiostatsBrad
Member
456
2,345
Jul 2024
Durham, NC
Jul 23, 2025 at 11:07 PM#14
CanadaChris said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

References:
[1] Zheng SL, et al. Lancet Diabetes Endocrinol. 2023;11(12):869-879.
27 2james_edin, FranDenver, Dr.BariatricHTX and 24 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jul 25, 2025 at 2:41 PM#15

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. Report rather than reply if it drifts again.

Last edited: Jul 25, 2025 at 6:41 PM
26 1PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 23 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register